ALLMedicine™ Schnitzler Syndrome Center

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

Feb 2nd, 2023 - History All patients with Schnitzler syndrome present with a chronic, recurrent, urticarial eruption. Pruritus is usually absent at the disease onset, but lesions may become mildly pruritic in approximately 45% of patients after 3-4 years. The ski...

Feb 2nd, 2023 - Antineoplastics, Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) View full drug information Ibrutinib inhibits the function of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor-signaling complex that plays an imp...

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

Dec 22nd, 2022 - The study will include a screening period (up to 28 days), a double blind, placebo controlled treatment period (14 days), followed by an 8 week safety follow up period after the second dose of study drug. Subjects with an established diagnosis of ...

Jul 5th, 2019 - Description of the study: Objectives: Primary objective: To evaluate if canakinumab 150mg every 8 weeks can induce and maintain clinical remission in patients with the Schnitzler syndrome. Secondary objectives: To test if canakinumab 150mg can ind...

Jul 17th, 2018 - This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome. Efficacy is asses...

Sep 8th, 2017 - The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component. Other frequent signs include joint, bone and muscle pain, enlarged spleen, liver and lymph nodes, increa...

May 31st, 2012 - This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany. Prospective subjects will be recruited from a patient population previously...

Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...

Sep 1st, 2022 - Background Schnitzler syndrome is a rare, auto-inflammatory syndrome associated with IgM monoclonal gammopathy that manifests as a non-pruritic urticarial rash. Patients may also have intermittent fevers, lymphadenopathy, bone pain, and arthralgia.

Sep 3rd, 2014 - To the Editor: Schnitzler syndrome occurs with a triad of chronic urticaria, recurring fevers, and monoclonal gammopathy. It was recognized as a clinical entity in 1972; now nearly 200 patients are reported in the medical literature.